News

Tempest Receives Orphan Drug Designation From The European Medicines Agency For Amezalpat For The Treatment Of Patients With HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgen ...
Consilium1d
The pharma package: new EU rules on medicines
The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...
Tempest Therapeutics stock rises on EMA Orphan Drug Designation
Investing.com -- Shares of Tempest Therapeutics Inc (NASDAQ: TPST) climbed 5.3% following the announcement that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its cancer ...
Medical Dialogues6h
Roche Evrysdi tablet gets European Commission approval for Spinal Muscular Atrophy
Basel: Roche has announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to ...
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...
Medscape12d
Blenrep Gets European Nod to Treat Multiple Myeloma
Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...
Pharmabiz11h
European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy
European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...